BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 30066941)

  • 1. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitin specific peptidase 19 is a prognostic biomarker and affect the proliferation and migration of clear cell renal cell carcinoma.
    Hu W; Su Y; Fei X; Wang X; Zhang G; Su C; Du T; Yang T; Wang G; Tang Z; Zhang J
    Oncol Rep; 2020 Jun; 43(6):1964-1974. PubMed ID: 32236633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
    Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
    Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
    Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
    Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of cyclin F/CCNF as an independent prognostic factor for poor survival in clear cell renal cell carcinoma.
    Kwiatkowski M; Krajewski A; Durślewicz J; Buchholz K; Grzanka D; Gagat M; Zabrzyński J; Klimaszewska-Wiśniewska A
    Sci Rep; 2024 Apr; 14(1):9280. PubMed ID: 38654021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA‑663 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells by directly targeting PAK4.
    Liu Y; Jiao D; Tian Z
    Mol Med Rep; 2019 Jan; 19(1):711-718. PubMed ID: 30431118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma.
    Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B
    BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma.
    Yoshino H; Yonezawa T; Yonemori M; Miyamoto K; Sakaguchi T; Sugita S; Osako Y; Tatarano S; Nakagawa M; Enokida H
    Oncol Rep; 2018 Jan; 39(1):173-181. PubMed ID: 29192325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
    Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
    Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
    Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
    Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
    Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
    Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma.
    Su H; Wang H; Shi G; Zhang H; Sun F; Ye D
    Eur J Surg Oncol; 2018 Jun; 44(6):840-846. PubMed ID: 29433989
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pan H; Hong Y; Yu B; Li L; Zhang X
    Cancer Biother Radiopharm; 2019 Jun; 34(5):334-341. PubMed ID: 30844301
    [No Abstract]   [Full Text] [Related]  

  • 18. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
    Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.